$312.05
0.38% yesterday
NYSE, May 29, 10:10 pm CET
ISIN
US1255091092
Symbol
CI

Cigna Stock price

$312.05
-25.16 7.46% 1M
-25.75 7.62% 6M
+35.91 13.00% YTD
-20.87 6.27% 1Y
+39.65 14.56% 3Y
+114.73 58.14% 5Y
+171.22 121.58% 10Y
NYSE, Closing price Thu, May 29 2025
+1.19 0.38%
ISIN
US1255091092
Symbol
CI
Sector

Key metrics

Market capitalization $83.36b
Enterprise Value $104.75b
P/E (TTM) P/E ratio 16.92
EV/FCF (TTM) EV/FCF 17.43
EV/Sales (TTM) EV/Sales 0.41
P/S ratio (TTM) P/S ratio 0.33
P/B ratio (TTM) P/B ratio 2.09
Dividend yield 1.79%
Last dividend (FY24) $5.60
Revenue growth (TTM) Revenue growth 23.96%
Revenue (TTM) Revenue $255.37b
EBIT (operating result TTM) EBIT $9.59b
Free Cash Flow (TTM) Free Cash Flow $6.01b
Cash position $9.06b
EPS (TTM) EPS $18.44
P/E forward 13.21
P/S forward 0.32
EV/Sales forward 0.41
Short interest 1.58%
Show more

Is Cigna a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Cigna Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Cigna forecast:

20x Buy
77%
6x Hold
23%

Analyst Opinions

26 Analysts have issued a Cigna forecast:

Buy
77%
Hold
23%

Financial data from Cigna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
255,368 255,368
24% 24%
100%
- Direct Costs 229,182 229,182
27% 27%
90%
26,186 26,186
2% 2%
10%
- Selling and Administrative Expenses 14,898 14,898
3% 3%
6%
- Research and Development Expense - -
-
-
11,288 11,288
2% 2%
4%
- Depreciation and Amortization 1,702 1,702
5% 5%
1%
EBIT (Operating Income) EBIT 9,586 9,586
3% 3%
4%
Net Profit 5,034 5,034
39% 39%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Cigna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cigna Stock News

Neutral
Business Wire
7 days ago
ARLINGTON, Va. & REYKJAVIK, Iceland--(BUSINESS WIRE)-- #kerecis--Cigna Insurance Company now includes Kerecis products in its medical coverage policy for the treatment of diabetic foot ulcers.
Positive
Reuters
8 days ago
Cigna said on Wednesday it was launching an add-on to pharmacy benefit management plans in which patients could pay no more than $200 a month out-of-pocket for weight-loss drugs Wegovy and Zepbound.
Positive
CNBC
8 days ago
Cigna's Evernorth unit said a new coverage deal with Eli Lilly and Novo Nordisk will bring lower copays for insured patients The company hopes the new discount, which caps monthly out-of-pocket costs at $200 for Wegovy and Zepbound, will convince more employers to offer coverage of the drugs.
More Cigna News

Company Profile

Cigna Corp. engages in the provision of global health services. It operates through the following segments: Health Services, Integrated Medical, International Markets, and Group Disability and Other. The Health Services segment includes pharmacy benefits management, specialty pharmacy services, clinical solutions, home delivery, and health management services. The Integrated Medical segment offers a variety of health care solutions to employers and individuals. The International Markets segment covers supplemental health, life and accident insurance products; and health care coverage in its international markets as well as health care benefits to globally mobile employees of multinational organizations. The Group Disability and Other segment represents group disability and life, corporate-owned life insurance, and run-off business consisting of reinsurance; settlement authority; and individual life insurance and annuity and retirement benefits business. The company was founded in 1792 and is headquartered in Bloomfield, CT.

Head office United States
CEO David Cordani
Employees 72,398
Founded 1792
Website www.thecignagroup.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today